Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden

Primary Care Diabetes

Volumn 5, Issue 2, 2011, Pages 89-94

  Berntorp, Kerstin ^a   Haglund, Mattias ^b   Larsen, Sara ^b   Petruckevitch, Ann ^c   Landin Olsson, Mona ^a  

^a LUND UNIVERSITY   (Sweden)

^b Novo Nordisk Scandinavia   (Sweden)

^c Novo Nordisk Ltd   (United Kingdom)

Author keywords

Biphasic insulin aspart 30; Glycaemic control; Hypoglycaemia; Insulin analogue; Premixed insulin; Primary care

Indexed keywords

BIPHASIC INSULIN; HEMOGLOBIN A1C; INSULIN ASPART;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DIABETIC PATIENT; DOCUMENTATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SERVICES RESEARCH; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958858255     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2011.02.003     Document Type: Article

References (16)

1. D.M. Nathan, J.B. Buse, M.B. Davidson, et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diab. Care 32 (2009) 193-203.
2. R.R. Holman, S.K. Paul, M.A. Bethel, et al., 10-year follow-up of intensive glucose control in type 2 diabetes, N. Engl. J. Med. 359 (2008) 1577-1589.
3. D. Khutsoane, S.K. Sharma, M. Almustafa, et al., Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study, Diab. Obes. Metab. 10 (2008) 212-222. (Pubitemid 351247337)
4. R. Qayyum, S. Bolen, N. Maruthur, et al., Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes, Ann. Intern. Med. 149 (2008) 549-559.
5. D. Cucinotta, G.T. Russo, Biphasic insulin aspart in the treatment of type 2 diabetes mellitus, Exp. Opin. Pharmacother. 10 (2009) 2905-2911.
6. M. Korytkowski, When oral agents fail: practical barriers to starting insulin, Int. J. Obes. Relat. Metab. Disord. 26S3 (2002) S18-S24. (Pubitemid 35034478)
7. S.A. Oliveria, L.A. Menditto, M. Ulcickas Yood, et al., Barriers to the initiation of, and persistence with, insulin therapy, Curr. Med. Res. Opin. 23 (2007) 3105-3112.
8. W. Hoelzel, C. Weykamp, J.O. Jeppsson, et al., IFCC reference system for measurement of haemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study, Clin. Chem. 1 (2004) 166-174. (Pubitemid 38125714)
9. A. Liebl, R. Prager, K. Binz, et al., Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial, Diab. Obes. Metab. 11 (2009) 45-52.
10. A.J. Garber, J. Wahlen, T. Wahl, et al., Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study), Diab. Obes. Metab. 8 (2006) 58-66.
11. P.H. Kann, T. Wascher, V. Zackova, et al., Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride, Exp. Clin. Endocrinol. Diab. 114 (2006) 527-532. (Pubitemid 44870902)
12. R.R. Holman, K.I. Thorne, A.J. Farmer, et al., Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes, N. Engl. J. Med. 357 (2007) 1716-1730.
13. P. Raskin, E. Allen, P. Hollander, et al., Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs, Diab. Care 28 (2005) 260-265. (Pubitemid 40170923)
14. P. Raskin, Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes, Diab. Metab. Res. Rev. 24 (2008) 3-13. (Pubitemid 351175995)
15. P. Valensi, M. Benroubi, V. Borzi, et al., The IMPROVE study-a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts, Int. J. Clin. Pract. 62 (2008) 1809-1819.
16. M. Shestakova, O.M. Bech, M.S. Momani, Study design and baseline characteristics of patients in the PRESENT study, Diab. Res. Clin. Pract. 81S1 (2008) S3-S9.